Bruker and 3M Sign Exclusive Patent License Agreement
04 June 2013 - 9:00PM
Business Wire
Bruker Corporation today announced that it has signed an
exclusive patent license agreement with 3M Company, which allows
Bruker to include 3M patented innovations relating to
matrix-assisted laser desorption ionization (MALDI) mass
spectrometry imaging.
The licensed 3M patents are directed to a technique for
performing mass spectrometry analysis on proteins in tissue that
has been preserved in paraffin. The technology enables researchers
to more easily study formalin-fixed, paraffin-embedded (FFPE)
tissue for life-science research and drug development.
MALDI imaging has been increasingly used to analyze clinically
relevant tissues such as tumor biopsies. The molecular phenotypes
observed by MALDI imaging have been shown to correlate with
parameters such as disease status or patient outcome, and have been
successfully applied to the classification of tissue samples.
MALDI imaging was originally developed for the analysis of
fresh, frozen tissue sections, but the analysis of preserved FFPE
tissue sections is becoming increasingly important due to
methodological improvements. In the MALDI imaging community it is
widely accepted that a meaningful analysis of FFPE tissue requires
a pretreatment called antigen-retrieval.
Dr. S�ren-Oliver Deininger, Market Manager for MALDI imaging at
Bruker, stated: “The interest in the analysis of FFPE tissue by
MALDI imaging is increasing strongly. Bruker has developed
innovative technology to make MALDI imaging viable in
histopathology by the integration of virtual microscopy and the
possibility to classify tissue based on the molecular phenotypes
(class-imaging). Our license agreement with 3M shows our ongoing
commitment to the MALDI imaging field, and gives our customers the
necessary freedom to conduct their research and advance the
field.”
“We are pleased to license these patents to Bruker, a leader in
the field of MALDI imaging, and see this technology applied in the
market,” said Dr. Todd Fruchterman, Senior Vice President of
Research & Development and Chief Medical Officer for 3M Health
Care. “We hope that this license agreement will accelerate the
research in MALDI imaging of FFPE tissue, and enable it to
ultimately become a valuable diagnostic tool.”
Dr. Hartmut Schlüter, Professor at the University Medical Center
Hamburg-Eppendorf, has recently published a MALDI imaging study on
more than 1,000 FFPE prostate cancer samples using Bruker’s MALDI
Molecular Imager solution. He explained: “FFPE tissue is
particularly important for the analysis by MALDI imaging because of
the large available archives of such tissue with patient follow-up
data and the possibility to use tissue microarrays for the
analysis. Furthermore, FFPE tissue is the standard for
histopathological diagnosis. Any future diagnostic application of
MALDI imaging will likely need to be established on FFPE
tissue.”
Note: Bruker MALDI imaging systems and solutions are for
research use only (RUO).
ABOUT 3M COMPANY (NYSE: MMM)
3M captures the spark of new ideas and transforms them into
thousands of ingenious products. Our culture of creative
collaboration inspires a never-ending stream of powerful
technologies that make life better. 3M is the innovation company
that never stops inventing. With $30 billion in sales, 3M employs
about 88,000 people worldwide and has operations in more than 70
countries. For more information, visit www.3M.com or follow @3MNews
on Twitter.
ABOUT BRUKER CORPORATION (NASDAQ: BRKR)
Bruker is a leading provider of high-performance scientific
instruments and solutions for molecular and materials research, as
well as for industrial, diagnostics and applied analysis. For more
information: www.bruker.com
Bruker Daltonik GmbH, Bremen, GermanyDr. S�ren Deininger,
+49-421-2205-270Soeren-Oliver.Deininger@bdal.deorBruker
DaltonicsVicky Lander, +1-978-663-3660Director of Global Marketing
Communications Servicesvicky.lander@bdal.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024